ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

24,492Medicare Part D Prescriptions Filled, Including Refills

Rank: 27 out of 955

$1.1M Total Retail Price of All Prescriptions

Rank: 37 out of 955

687 Patients Receiving at Least One Drug in Part D
76% Patients 65 Years and Older
57% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Arkansas
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

9% of this provider’s 687 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

27% of this provider’s 687 patients filled at least one prescription for a schedule three drug, compared to an average of 18%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 19%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $47 among peers.

Prescriptions per Patient

36 is the average number of prescriptions (including refills) per patient, compared to an average of 23.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
HYDROCODONE-ACETAMINOPHEN 905 676 176 S3 1 1
LISINOPRIL 816 642 133 2 2
LEVOTHYROXINE SODIUM 695 547 96 3 3
PRAVASTATIN SODIUM 688 579 111 4 11
GABAPENTIN 621 368 102 5 10
OMEPRAZOLE 611 417 107 6 5
FUROSEMIDE 565 458 95 7 7
CITALOPRAM HBR 563 424 94 8 16
ATENOLOL 559 424 93 9 21
METFORMIN HCL 526 438 83 10 8
AMLODIPINE BESYLATE 505 415 89 11 6
POTASSIUM CHLORIDE 436 329 71 12 9
ZOLPIDEM TARTRATE 369 239 71 13 24
TAMSULOSIN HCL 365 324 67 14 29
WARFARIN SODIUM 343 292 54 15 19
METOPROLOL SUCCINATE 340 272 52 16 23
NAMENDA 306 306 22 17 35
TRAMADOL HCL 297 180 72 18 17
ATORVASTATIN CALCIUM 287 227 56 19 13
LISINOPRIL-HYDROCHLOROTHIAZIDE 276 231 47 20 22
LOSARTAN-HYDROCHLOROTHIAZIDE 274 203 39 21 53
SIMVASTATIN 271 232 53 22 4
SERTRALINE HCL 262 205 48 23 26
METOPROLOL TARTRATE 256 169 46 24 12
LOSARTAN POTASSIUM 248 189 47 25 28
CLONAZEPAM 245 156 44 B 26 32
NEXIUM 233 146 30 27 25
HYDROCHLOROTHIAZIDE 225 173 37 28 14
FAMOTIDINE* 224 170 60 29 67
LORAZEPAM 222 163 66 B 30 31
MELOXICAM 211 137 40 31 15
CARVEDILOL 206 168 36 32 27
DONEPEZIL HCL 184 184 27 33 33
PREDNISONE 181 142 93 34 47
ALLOPURINOL 163 147 25 35 34
MIRTAZAPINE 160 155* 36 36 60
FLUTICASONE PROPIONATE 155 86 58 37 38
QUETIAPINE FUMARATE 152 127 17 A 38 56
ALPRAZOLAM 147 100 22 B 39 20
DIOVAN 146 141* 17 40 57
CYMBALTA 145 80 20 41 43
TRAZODONE HCL 143 104 31 42 30
PANTOPRAZOLE SODIUM 133 119 28 43 42
PROAIR HFA 131 95 29 44 36
ESCITALOPRAM OXALATE 130 108 18 45 46
GLIMEPIRIDE 130 87 25 45 37
CLOPIDOGREL 127 95 22 47 18
HYDRALAZINE HCL 124 80 23 48 127
AZITHROMYCIN 123 98 106 49 41
DIVALPROEX SODIUM 123 77 19 49 106
TEMAZEPAM 119 102 34 B 51 93
CIPROFLOXACIN HCL 118 106 83 52 58
SPIRIVA 116 97 27 53 74
LANTUS SOLOSTAR 110 92 26 54 99
AMITRIPTYLINE HCL 107 67 15 R 55 45
OXYCODONE-ACETAMINOPHEN 106 92 32 S2 56 136
CLONIDINE HCL 104 70 21 57 44
METFORMIN HCL ER 103 98* 13 58 66
TRIAMTERENE-HCTZ 100 71 19 59 39
PIOGLITAZONE HCL 99 79 13 R 60 100
FENTANYL 96 55 18 S2 61 109
MONTELUKAST SODIUM 94 45 15 62 61
DILTIAZEM 24HR CD 93 88* 18 63 147
AMOXICILLIN 92 73 77 64 87
ISOSORBIDE MONONITRATE ER 92 71 17 64 55
GLIPIZIDE 91 86* 15 66 50
VALSARTAN-HYDROCHLOROTHIAZIDE 91 86* 13 66 81
PREMARIN 88 44 13 R 68 141
VENLAFAXINE HCL ER 87 74 15 69 98
ESTRADIOL 87 43 14 R 69 84
IPRATROPIUM-ALBUTEROL 85 <11 <11 71 175
FLUOXETINE HCL 84 39 17 72 48
CARBIDOPA-LEVODOPA 84 37 12 72 116
ROPINIROLE HCL 83 49 22 74 82
RISPERIDONE 83 59 13 A 74 90
CRESTOR 83 62 17 74 49
SYNTHROID 80 67 11 77 73
MUPIROCIN* 79 58 41 78 185
AMLODIPINE BESYLATE-BENAZEPRIL 76 76 13 79 76
FENOFIBRATE* 75 <11 <11 80 83
ADVAIR DISKUS 75 56 14 80 69
TRIAMCINOLONE ACETONIDE 73 57 43 82 146
VENTOLIN HFA 73 59 27 82 94
NAPROXEN 73 43 21 82 78
ATENOLOL-CHLORTHALIDONE 72 52 12 85 165
CYCLOBENZAPRINE HCL 72 31 24 R 85 54
BUPROPION XL 71 59 12 87 160
PRAMIPEXOLE DIHYDROCHLORIDE 70 <11 <11 88 148
LEVOFLOXACIN 69 56 56 89 77
TIZANIDINE HCL 66 12 15 90 65
DIGOXIN 65 <11 <11 91 137
FINASTERIDE 64 <11 <11 92 119
EXELON 64 64 11 92 156
OLANZAPINE 62 <11 <11 A 94 134
CELEBREX 61 34 11 95 105
MORPHINE SULFATE ER 60 <11 <11 S2 96 112
NIASPAN 59 34 12 97 192
BENAZEPRIL HCL 59 <11 <11 97 88
LYRICA 58 <11 <11 99 63
MEGESTROL ACETATE 56 51* 17 R 100 152
LAMOTRIGINE 55 50* 13 101 173
AMIODARONE HCL 55 <11 <11 101 150
FLOVENT HFA 54 36 11 103 255
KLOR-CON M10 53 <11 <11 104 178
PROPRANOLOL HCL 52 <11 <11 105 120
LANSOPRAZOLE 51 <11 <11 106 180
PHENYTOIN SODIUM EXTENDED 51 <11 <11 106 111
ALENDRONATE SODIUM 50 36 13 108 51
BD ULTRA-FINE PEN NEEDLE 50 35 15 108 179
ETODOLAC 50 <11 <11 108 217
PRIMIDONE 50 45* 13 108 243
FLUCONAZOLE 50 26 34 108 139
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 13, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.